ViBA

Assessment of Bioequivalence of Weak Base Formulations Under Various Dosing Conditions Using Physiologically Based Pharmacokinetic Simulations in Virtual Populations. Case Examples: Ketoconazole and Posaconazole.

Cristofoletti R, Patel N, Dressman JB. · Journal of pharmaceutical sciences · 2017 · Article

10.1016/j.xphs.2016.10.008

Verified evidence

Model scenario comparison

c6824499-5696-5d4d-91ee-cadce38c686d
Area under the curve (AUC)Pharmacokinetics and drug exposure

Prediction source Publisher proof · PDF page(s) 6

Study 314ee01c-e0d3-5aee-85a5-5ec902c51298 · Prediction record (JSON)

Prediction fields

Endpoint
peak_concentration · PDF page(s) 6
Family
pharmacokinetic_exposure · PDF page(s) 6
Measured variable
peak_concentration · PDF page(s) 6
Metric
peak · PDF page(s) 6
Model
mechanistic_or_numerical · PDF page(s) 1
Population
simulated_system · PDF page(s) 1, 6